LoDoCo2 Trial
New England Journal of Medicine (2020)
0.5mg daily reduced MACE by 31% (HR 0.69) in 5,522 stable CAD patients on background statin/antiplatelet.
Colchicine
Oral tablet (0.6mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
ColchicineColchicine
Ancient alkaloid with potent anti-inflammatory properties. LoDoCo2 and COLCOT trials demonstrated 0.5mg daily significantly reduces MACE in stable CAD and post-ACS, targeting residual inflammatory risk not addressed by lipid lowering.
31% MACE reduction in stable CAD (LoDoCo2)
23% MACE reduction post-ACS (COLCOT)
Targets NLRP3/IL-1beta, additive to statins
Low cost (generic)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Inhibits tubulin polymerization, disrupting NLRP3 inflammasome activation, neutrophil chemotaxis, and IL-1beta/IL-18 secretion. Potent inhibition of innate inflammatory response underlying plaque destabilization.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Colchicine.
COLCOT Trial
New England Journal of Medicine (2019)
0.5mg daily reduced MACE by 23% when initiated within 30 days of MI.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- GI intolerance, nausea, diarrhea (10%)
- Myalgia
- Fatigue
Less common but serious risks
- Myopathy/neuromuscular toxicity (with CYP3A4/P-gp inhibitors)
- Colchicine toxicity/overdose, potentially fatal
- Bone marrow suppression (chronic high-dose)
- Azoospermia (temporary)
Generally not appropriate for
- Severe renal impairment (eGFR <15)
- Severe hepatic impairment
- Strong CYP3A4/P-gp inhibitors (cyclosporine, clarithromycin)
Typical monitoring
- CBC
- Renal function
- Liver function
- Drug interaction screening
- GI symptoms
FAQ
Quick answers.
Ancient alkaloid with potent anti-inflammatory properties. LoDoCo2 and COLCOT trials demonstrated 0.5mg daily significantly reduces MACE in stable CAD and post-ACS, targeting residual inflammatory risk not addressed by lipid lowering.
31% MACE reduction in stable CAD (LoDoCo2). 23% MACE reduction post-ACS (COLCOT). Targets NLRP3/IL-1beta, additive to statins. Low cost (generic). Once-daily dosing.
Common side effects include: gi intolerance, nausea, diarrhea (10%), myalgia, fatigue. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Ancient alkaloid with potent anti-inflammatory properties. LoDoCo2 and COLCOT trials demonstrated 0.5mg daily significantly reduces MACE in stable CAD and post-ACS, targeting residual inflammatory risk not addressed by lipid lowering.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.